Peter Haeberli
Corporate Officer/Principal at The Colorado Bar Association
Profile
Mr. Peter Haeberli is Of Counsel at Moderna Therapeutics, Inc. and a Member at The Colorado Bar Association.
Mr. Haeberli was previously employed as Managing Counsel by Merck & Co., Inc., a Director-Intellectual Property by Sirna Therapeutics, Inc., Chemist by Ciba-Geigy Corp., and a Principal by Sandoz, Inc.
He received his undergraduate degree from The University of Colorado and a graduate degree from the Sturm College of Law.
Peter Haeberli active positions
| Companies | Position | Start |
|---|---|---|
| The Colorado Bar Association | Corporate Officer/Principal | - |
Former positions of Peter Haeberli
| Companies | Position | End |
|---|---|---|
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | - |
| Ciba-Geigy Corp. | Corporate Officer/Principal | - |
| MERCK & CO., INC. | General Counsel | - |
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | - |
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | General Counsel | - |
Training of Peter Haeberli
| The University of Colorado | Undergraduate Degree |
| Sturm College of Law | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Private companies | 5 |
|---|---|
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Health Technology |
| The Colorado Bar Association | |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
| Ciba-Geigy Corp. | Health Technology |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Health Technology |
- Stock Market
- Insiders
- Peter Haeberli
